Loading clinical trials...
Loading clinical trials...
Real-world Assessment of Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
Conditions
Interventions
Trilaciclib Injection [Cosela]
Locations
1
China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Start Date
April 2, 2024
Primary Completion Date
December 31, 2024
Completion Date
April 2, 2025
Last Updated
November 21, 2024
NCT07463573
NCT06764355
NCT07359417
NCT04686682
NCT05473156
NCT06709417
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions